![The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con - The Con Side - ILCN.org (ILCN/WCLC) The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con - The Con Side - ILCN.org (ILCN/WCLC)](https://www.ilcn.org/wp-content/uploads/2021/12/Shepard_Rimner-300x169.jpg)
The Role of PORT in Patients With Completely Resected Stage III-N2 NSCLC: A Pro/Con - The Con Side - ILCN.org (ILCN/WCLC)
![Predictors of survival following surgical resection of limited-stage small cell lung cancer - ScienceDirect Predictors of survival following surgical resection of limited-stage small cell lung cancer - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0022522320331378-gr5.jpg)
Predictors of survival following surgical resection of limited-stage small cell lung cancer - ScienceDirect
![Cancers | Free Full-Text | Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer—A Review Cancers | Free Full-Text | Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer—A Review](https://www.mdpi.com/cancers/cancers-14-01617/article_deploy/html/images/cancers-14-01617-g001.png)
Cancers | Free Full-Text | Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer—A Review
![Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial - The Lancet Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial - The Lancet](https://www.thelancet.com/cms/attachment/01910c4d-4153-4fb3-83fc-3f2643284883/gr1_lrg.gif)
Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART, IFCT 0503): an open-label, randomised, phase 3 trial - The Lancet
![A 77-year-old man with lung cancer presented with malfunction of the... | Download Scientific Diagram A 77-year-old man with lung cancer presented with malfunction of the... | Download Scientific Diagram](https://www.researchgate.net/publication/309876357/figure/fig6/AS:427299683213315@1478887591956/A-77-year-old-man-with-lung-cancer-presented-with-malfunction-of-the-port-due-to.png)
A 77-year-old man with lung cancer presented with malfunction of the... | Download Scientific Diagram
![port a cath, non small cell lung cancer, lung cancer, treatment of lung cancer, chemotherapy, oncology, USMLE, ABIM, board review, oncologist, avastin, erlotinib, EGFR mutation, cetuximab, port a cath, non small cell lung cancer, lung cancer, treatment of lung cancer, chemotherapy, oncology, USMLE, ABIM, board review, oncologist, avastin, erlotinib, EGFR mutation, cetuximab,](http://www.hemonc101.com/v/vspfiles/assets/images/portacath_chest_small.jpg)